Top

Published in:

22-10-2023 | Sudden Cardiac Death

Current perspectives of sudden cardiac death management in hypertrophic cardiomyopathy

Authors: Lutong Pu, Jialin Li, Weitang Qi, Jinquan Zhang, Hongyu Chen, Zihuan Tang, Yuchi Han, Jie Wang, Yucheng Chen

Published in: Heart Failure Reviews | Issue 2/2024

Abstract

Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder characterized by left ventricular hypertrophy. Sudden cardiac death (SCD) is a rare but the most catastrophic complication in patients with HCM. Implantable cardioverter-defibrillators (ICDs) are widely recognized as effective preventive measures for SCD. Individualized risk stratification and early intervention in HCM can significantly improve patient prognosis. In this study, we review the latest findings regarding pathogenesis, risk stratification, and prevention of SCD in HCM patients, highlighting the clinic practice of cardiovascular magnetic resonance imaging for SCD management.

Semsarian C, Ingles J, Maron MS, Maron BJ (2015) New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65(12):1249–1254. https://doi.org/10.1016/j.jacc.2015.01.019CrossRefPubMed

Nishimura RA, Ommen SR, Tajik AJ (2003) Cardiology patient page. Hypertrophic cardiomyopathy: a patient perspective Circulation 108(19):e133–e135PubMed

Maron BJ, Rowin EJ, Maron MS (2018) Global burden of hypertrophic cardiomyopathy. JACC Heart Fail 6(5):376–378. https://doi.org/10.1016/j.jchf.2018.03.004CrossRefPubMed

Maron BJ, Rowin EJ, Casey SA, Maron MS (2016) How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice. JAMA Cardiol 1(1). https://doi.org/10.1001/jamacardio.2015.0354

Park YM (2023) Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator. Korean J Intern Med 38(1). https://doi.org/10.3904/kjim.2022.144

Maron BJ, Rowin EJ, Maron MS (2021) Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: twenty years with the implantable cardioverter-defibrillator. Heart Rhythm 18(6):1012–1023. https://doi.org/10.1016/j.hrthm.2021.01.019CrossRefPubMed

Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al (2020) 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 142(25):e558–e631. https://doi.org/10.1161/CIR.0000000000000937CrossRefPubMed

Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733–2779. https://doi.org/10.1093/eurheartj/ehu284CrossRefPubMed

Maron BJ, Maron MS, Maron BA, Loscalzo J (2019) Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy: JACC review topic of the week. J Am Coll Cardiol 73(15):1978–1986. https://doi.org/10.1016/j.jacc.2019.01.061CrossRefPubMedPubMedCentral

10.

Maron BJ, Maron MS (2013) Hypertrophic cardiomyopathy. Lancet (London, England) 381(9862):242–255. https://doi.org/10.1016/S0140-6736(12)60397-3CrossRefPubMedADS

11.

Seidman CE, Seidman JG (2011) Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res 108(6):743–750. https://doi.org/10.1161/CIRCRESAHA.110.223834CrossRefPubMed

12.

Marian AJ, Braunwald E (2017) Hypertrophic cardiomyopathy genetics, Pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121(7):749–770. https://doi.org/10.1161/circresaha.117.311059CrossRefPubMedPubMedCentral

13.

Prondzynski M, Mearini G, Carrier L (2019) Gene therapy strategies in the treatment of hypertrophic cardiomyopathy. Pflugers Arch 471(5):807–815. https://doi.org/10.1007/s00424-018-2173-5CrossRefPubMed

14.

Khera AV, Mason-Suares H, Brockman D, Wang M, VanDenburgh MJ, Senol-Cosar O et al (2019) Rare genetic variants associated with sudden cardiac death in adults. J Am Coll Cardiol 74(21):2623–2634. https://doi.org/10.1016/j.jacc.2019.08.1060CrossRefPubMedPubMedCentral

15.

Shen H, Dong S-Y, Ren M-S, Wang R (2022) Ventricular arrhythmia and sudden cardiac death in hypertrophic cardiomyopathy: from bench to bedside. Frontiers In Cardiovascular Medicine 9:949294. https://doi.org/10.3389/fcvm.2022.949294CrossRefPubMedPubMedCentral

16.

Chida A, Inai K, Sato H, Shimada E, Nishizawa T, Shimada M et al (2017) Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy. Heart Vessels 32(6):700–707. https://doi.org/10.1007/s00380-016-0920-0CrossRefPubMed

17.

Fraysse B, Weinberger F, Bardswell SC, Cuello F, Vignier N, Geertz B et al (2012) Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol 52(6):1299–1307. https://doi.org/10.1016/j.yjmcc.2012.03.009CrossRefPubMedPubMedCentral

18.

Jacoby D, McKenna WJ (2012) Genetics of inherited cardiomyopathy. Eur Heart J 33(3):296–304. https://doi.org/10.1093/eurheartj/ehr260CrossRefPubMed

19.

Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA et al (2022) 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 43(40):3997–4126. https://doi.org/10.1093/eurheartj/ehac262CrossRefPubMed

20.

Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C et al (2023) 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. https://doi.org/10.1093/eurheartj/ehad194CrossRefPubMed

21.

Finocchiaro G, Sheikh N, Leone O, Westaby J, Mazzarotto F, Pantazis A et al (2021) Arrhythmogenic potential of myocardial disarray in hypertrophic cardiomyopathy: genetic basis, functional consequences and relation to sudden cardiac death. Europace 23(7):985–995. https://doi.org/10.1093/europace/euaa348CrossRefPubMed

22.

Pelliccia F, Cecchi F, Olivotto I, Camici PG (2022) Microvascular dysfunction in hypertrophic cardiomyopathy. J Clin Med 11(21). https://doi.org/10.3390/jcm11216560

23.

Maron BJ (2010) Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 121(3):445–456. https://doi.org/10.1161/CIRCULATIONAHA.109.878579CrossRefPubMed

24.

Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F et al (2013) Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 127(5):575–584. https://doi.org/10.1161/CIRCULATIONAHA.112.134932CrossRefPubMed

25.

Coppini R, Ferrantini C, Del Lungo M, Stillitano F, Sartiani L, Tosi B et al (2013) Response to letter regarding article, “Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.” Circulation 128(10):e157. https://doi.org/10.1161/CIRCULATIONAHA.113.004016CrossRefPubMed

26.

Tashiro N, Muneuchi J, Ezaki H, Kobayashi M, Yamada H, Sugitani Y et al (2022) Ventricular repolarization dispersion is a potential risk for the development of life-threatening arrhythmia in children with hypertrophic cardiomyopathy. Pediatr Cardiol 43(7):1455–1461. https://doi.org/10.1007/s00246-022-02867-3CrossRefPubMed

27.

Cheng Z, Fang T, Huang J, Guo Y, Alam M, Qian H (2021) Hypertrophic cardiomyopathy: from phenotype and pathogenesis to treatment. Frontiers In Cardiovascular Medicine 8:722340. https://doi.org/10.3389/fcvm.2021.722340CrossRefPubMedPubMedCentral

28.

Helms AS, Alvarado FJ, Yob J, Tang VT, Pagani F, Russell MW et al (2016) Genotype-dependent and -independent calcium signaling dysregulation in human hypertrophic cardiomyopathy. Circulation 134(22):1738–1748CrossRefPubMedPubMedCentral

29.

Okuda S, Sufu-Shimizu Y, Kato T, Fukuda M, Nishimura S, Oda T et al (2018) CaMKII-mediated phosphorylation of RyR2 plays a crucial role in aberrant Ca release as an arrhythmogenic substrate in cardiac troponin T-related familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun 496(4):1250–1256. https://doi.org/10.1016/j.bbrc.2018.01.181CrossRefPubMed

30.

Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO (2009) Sudden deaths in young competitive athletes. Circulation 119(8):1085–1092. https://doi.org/10.1161/circulationaha.108.804617CrossRefPubMed

31.

Finocchiaro G, Bhatia RT, Westaby J, Behr ER, Papadakis M, Sharma S et al (2023) Sudden cardiac death during exercise in young individuals with hypertrophic cardiomyopathy. JACC: Clin Electrophysiol 9(6):865–7. https://doi.org/10.1016/j.jacep.2022.12.007

32.

Sharma S, Pelliccia A, Gati S (2020) The ‘Ten Commandments’ for the 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa735CrossRefPubMedPubMedCentral

33.

Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al (2020) 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 142(25):e533–e557. https://doi.org/10.1161/CIR.0000000000000938CrossRefPubMed

34.

Sweeting J, Ingles J, Ball K, Semsarian C (2018) A control theory-based pilot intervention to increase physical activity in patients with hypertrophic cardiomyopathy. Am J Cardiol 122(5):866–871. https://doi.org/10.1016/j.amjcard.2018.05.023CrossRefPubMed

35.

Pelliccia A, Lemme E, Maestrini V, Di Paolo FM, Pisicchio C, Di Gioia G et al (2018) Does sport participation worsen the clinical course of hypertrophic cardiomyopathy? Circulation 137(5):531–533. https://doi.org/10.1161/circulationaha.117.031725CrossRefPubMed

36.

Lampert R, Ackerman MJ, Marino BS, Burg M, Ainsworth B, Salberg L et al (2023) Vigorous exercise in patients with hypertrophic cardiomyopathy. JAMA Cardiol 8(6). https://doi.org/10.1001/jamacardio.2023.1042

37.

Gati S, Sharma S (2022) Exercise prescription in individuals with hypertrophic cardiomyopathy: what clinicians need to know. Heart 108(24):1930–1937. https://doi.org/10.1136/heartjnl-2021-319861CrossRefPubMed

38.

Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE et al (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42(9):1687–713. https://doi.org/10.1016/s0735-1097(03)00941-0

39.

Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P et al (2019) Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy. JAMA Cardiol 4(7):644–657. https://doi.org/10.1001/jamacardio.2019.1391CrossRefPubMedPubMedCentral

40.

Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS et al (2017) Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol 69(7):761–773. https://doi.org/10.1016/j.jacc.2016.11.063CrossRefPubMed

41.

Lee DZJ, Montazeri M, Bataiosu R, Hoss S, Adler A, Nguyen ET et al (2022) Clinical characteristics and prognostic importance of left ventricular apical aneurysms in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 15(10):1696–1711. https://doi.org/10.1016/j.jcmg.2022.03.029CrossRefPubMed

42.

Debonnaire P, Katsanos S, Joyce E, OV VDB, Atsma DE, Schalij MJ et al (2015) QRS fragmentation and QTc duration relate to malignant ventricular tachyarrhythmias and sudden cardiac death in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 26(5):547–555. https://doi.org/10.1111/jce.12629CrossRefPubMed

43.

Dinshaw L, Munch J, Dickow J, Lezius S, Willems S, Hoffmann BA et al (2018) The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy. Clin Res Cardiol 107(2):130–137. https://doi.org/10.1007/s00392-017-1164-4CrossRefPubMed

44.

Wu G, Liu J, Wang S, Yu S, Zhang C, Wang D et al (2021) N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy. Heart 107(19):1576–1583. https://doi.org/10.1136/heartjnl-2020-317701CrossRefPubMed

45.

Ramchand J, Fava AM, Chetrit M, Desai MY (2020) Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathy. Heart 106(11):793–801. https://doi.org/10.1136/heartjnl-2019-315176CrossRefPubMed

46.

Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y et al (2016) Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging 9(12):1392–1402. https://doi.org/10.1016/j.jcmg.2016.02.031CrossRefPubMed

47.

Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130(6):484–495. https://doi.org/10.1161/CIRCULATIONAHA.113.007094CrossRefPubMed

48.

Li Y, Liu X, Yang F, Wang J, Xu Y, Fang T et al (2021) Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy. Eur Radiol 31(7):4557–4567. https://doi.org/10.1007/s00330-020-07650-7CrossRefPubMed

49.

Qin L, Min J, Chen C, Zhu L, Gu S, Zhou M et al (2021) Incremental values of T1 mapping in the prediction of sudden cardiac death risk in hypertrophic cardiomyopathy: a comparison with two guidelines. Front Cardiovasc Med 8:661673. https://doi.org/10.3389/fcvm.2021.661673CrossRefPubMedPubMedCentral

50.

Avanesov M, Munch J, Weinrich J, Well L, Saring D, Stehning C et al (2017) Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR. Eur Radiol 27(12):5136–5145. https://doi.org/10.1007/s00330-017-4869-xCrossRefPubMed

51.

Xu Z, Wang J, Cheng W, Wan K, Li W, Pu L et al (2023) Incremental significance of myocardial oedema for prognosis in hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. https://doi.org/10.1093/ehjci/jead065CrossRefPubMedPubMedCentral

52.

Yang F, Wang J, Li Y, Li W, Xu Y, Wan K et al (2019) The prognostic value of biventricular long axis strain using standard cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Int J Cardiol 294:43–49. https://doi.org/10.1016/j.ijcard.2019.08.010CrossRefPubMed

53.

Yang F, Wang L, Wang J, Pu L, Xu Y, Li W et al (2021) Prognostic value of fast semi-automated left atrial long-axis strain analysis in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 23(1):36. https://doi.org/10.1186/s12968-021-00735-2CrossRefPubMedPubMedCentral

54.

Wang J, Li Y, Yang F, Bravo L, Wan K, Xu Y et al (2021) Fractal analysis: prognostic value of left ventricular trabecular complexity cardiovascular MRI in participants with hypertrophic cardiomyopathy. Radiology 298(1):71–79. https://doi.org/10.1148/radiol.2020202261CrossRefPubMed

55.

Fahmy AS, Neisius U, Chan RH, Rowin EJ, Manning WJ, Maron MS et al (2020) Three-dimensional deep convolutional neural networks for automated myocardial scar quantification in hypertrophic cardiomyopathy: a multicenter multivendor study. Radiology 294(1):52–60. https://doi.org/10.1148/radiol.2019190737CrossRefPubMed

56.

Wang J, Bravo L, Zhang J, Liu W, Wan K, Sun J et al (2021) Radiomics analysis derived from LGE-MRI predict sudden cardiac death in participants with hypertrophic cardiomyopathy. Front Cardiovasc Med 8:766287. https://doi.org/10.3389/fcvm.2021.766287CrossRefPubMedPubMedCentral

57.

Zegkos T, Tziomalos G, Parcharidou D, Ntelios D, Papanastasiou CA, Karagiannidis E et al (2022) Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with hypertrophic cardiomyopathy. Hellenic J Cardiol 63:15–21. https://doi.org/10.1016/j.hjc.2021.06.005CrossRefPubMed

58.

Wang J, Zhang Z, Li Y, Xu Y, Wan K, Chen Y (2019) Variable and limited predictive value of the European Society of Cardiology hypertrophic cardiomyopathy sudden-death risk model: a meta-analysis. Can J Cardiol 35(12):1791–1799. https://doi.org/10.1016/j.cjca.2019.05.004CrossRefPubMed

59.

Taha M, Dahat P, Toriola S, Satnarine T, Zohara Z, Adelekun A et al (2023) Metoprolol or verapamil in the management of patients with hypertrophic cardiomyopathy: a systematic review. Cureus. https://doi.org/10.7759/cureus.43197CrossRefPubMedPubMedCentral

60.

Pollick C (1982) Muscular subaortic stenosis. N Engl J Med 307(16):997–999. https://doi.org/10.1056/nejm198210143071607CrossRefPubMed

61.

Adelman AG, Shah PM, Gramiak R, Wigle ED (1970) Long-term propranolol therapy in muscular subaortic stenosis. Heart 32(6):804–811. https://doi.org/10.1136/hrt.32.6.804CrossRef

62.

Hegde SM, Lester SJ, Solomon SD, Michels M, Elliott PM, Nagueh SF et al (2021) Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 78(25):2518–2532. https://doi.org/10.1016/j.jacc.2021.09.1381CrossRefPubMed

63.

Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP et al (2000) Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342(6):365–373. https://doi.org/10.1056/nejm200002103420601CrossRefPubMed

64.

Shun-Shin MJ, Zheng SL, Cole GD, Howard JP, Whinnett ZI, Francis DP (2017) Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials. Eur Heart J 38(22):1738–1746. https://doi.org/10.1093/eurheartj/ehx028CrossRefPubMedPubMedCentral

65.

Elliott P (2021) Sudden cardiac death in hypertrophic cardiomyopathy: time to change the narrative. Eur Heart J 42(38):3945–3947. https://doi.org/10.1093/eurheartj/ehab608CrossRefPubMed

Title: Current perspectives of sudden cardiac death management in hypertrophic cardiomyopathy
Authors: Lutong Pu
Jialin Li
Weitang Qi
Jinquan Zhang
Hongyu Chen
Zihuan Tang
Yuchi Han
Jie Wang
Yucheng Chen
Publication date: 22-10-2023
Publisher: Springer US
Keywords: Sudden Cardiac Death
Cardiomyopathy
Aneurysm
Aneurysm
Published in: Heart Failure Reviews / Issue 2/2024
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-023-10355-w

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Current perspectives of sudden cardiac death management in hypertrophic cardiomyopathy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

Device therapy for patients with atrial fibrillation and heart failure with preserved ejection fraction

Echocardiographic manifestations in end-stage renal disease

A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy

The sympathetic nervous system in heart failure revisited

The prevalence of coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis

Takotsubo pathophysiology and complications: what we know and what we do not know

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page